Search

Your search keyword '"Mikhailidis, Dimitri P."' showing total 2,158 results
Start Over Author "Mikhailidis, Dimitri P." Language english
2,158 results on '"Mikhailidis, Dimitri P."'

1. New-Onset Diabetes Mellitus in COVID-19: A Scoping Review

Author

Pantea Stoian, Anca, Bica, Ioana-Cristina, Salmen, Teodor, Al Mahmeed, Wael, Al-Rasadi, Khalid, Al-Alawi, Kamila, Banach, Maciej, Banerjee, Yajnavalka, Ceriello, Antonio, Cesur, Mustafa, Cosentino, Francesco, Firenze, Alberto, Galia, Massimo, Goh, Su-Yen, Janez, Andrej, Kalra, Sanjay, Kapoor, Nitin, Kempler, Peter, Lessan, Nader, Lotufo, Paulo, Mikhailidis, Dimitri P., Nibali, Luigi, Papanas, Nikolaos, Powell-Wiley, Tiffany, Rizvi, Ali A., Sahebkar, Amirhossein, Santos, Raul D., Toth, Peter P., Viswanathan, Vijay, and Rizzo, Manfredi

Published
2024
Full Text
View/download PDF

2. Correction to: New-Onset Diabetes Mellitus in COVID-19: A Scoping Review

Author

Pantea Stoian, Anca, Bica, Ioana-Cristina, Salmen, Teodor, Al Mahmeed, Wael, Al-Rasadi, Khalid, Al-Alawi, Kamila, Banach, Maciej, Banerjee, Yajnavalka, Ceriello, Antonio, Cesur, Mustafa, Cosentino, Francesco, Firenze, Alberto, Galia, Massimo, Goh, Su-Yen, Janez, Andrej, Kalra, Sanjay, Kapoor, Nitin, Kempler, Peter, Lessan, Nader, Lotufo, Paulo, Mikhailidis, Dimitri P., Nibali, Luigi, Papanas, Nikolaos, Powell-Wiley, Tiffany, Rizvi, Ali A., Sahebkar, Amirhossein, Santos, Raul D., Toth, Peter P., Viswanathan, Vijay, and Rizzo, Manfredi

Published
2024
Full Text
View/download PDF

4. Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review

Author

Singh, Manasvi, Kumar, Ashish, Khanna, Narendra N., Laird, John R., Nicolaides, Andrew, Faa, Gavino, Johri, Amer M., Mantella, Laura E., Fernandes, Jose Fernandes E., Teji, Jagjit S., Singh, Narpinder, Fouda, Mostafa M., Singh, Rajesh, Sharma, Aditya, Kitas, George, Rathore, Vijay, Singh, Inder M., Tadepalli, Kalyan, Al-Maini, Mustafa, Isenovic, Esma R., Chaturvedi, Seemant, Garg, Deepak, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Viswanathan, Vijay, Kalra, Manudeep K., Ruzsa, Zoltan, Saba, Luca, Laine, Andrew F., Bhatt, Deepak L., and Suri, Jasjit S.

Published
2024
Full Text
View/download PDF

6. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Brown, Martin M., Lal, Brajesh K., Myrcha, Piotr, Lyden, Sean P., Schneider, Peter A., Poredos, Pavel, Mikhailidis, Dimitri P., Secemsky, Eric A., Musialek, Piotr, Mansilha, Armando, Parikh, Sahil A., Silvestrini, Mauro, Lavie, Carl J., Dardik, Alan, Blecha, Matthew, Liapis, Christos D., Zeebregts, Clark J., Nederkoorn, Paul J., Poredos, Peter, Gurevich, Victor, Jawien, Arkadiusz, Lanza, Gaetano, Gray, William A., Gupta, Ajay, Svetlikov, Alexei V., Fernandes e Fernandes, Jose, Nicolaides, Andrew N., White, Christopher J., Meschia, James F., Cronenwett, Jack L., Schermerhorn, Marc L., and AbuRahma, Ali F.

Published
2024
Full Text
View/download PDF

7. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean-Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Jr., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans-Henning, Gloviczki, Peter, and White, Christopher J.

Published
2024
Full Text
View/download PDF

8. Carotid Plaque-RADS: A Novel Stroke Risk Classification System

Author

Saba, Luca, Cau, Riccardo, Murgia, Alessandro, Nicolaides, Andrew N., Wintermark, Max, Castillo, Mauricio, Staub, Daniel, Kakkos, Stavros K., Yang, Qi, Paraskevas, Kosmas I., Yuan, Chun, Edjlali, Myriam, Sanfilippo, Roberto, Hendrikse, Jeroen, Johansson, Elias, Mossa-Basha, Mahmud, Balu, Niranjan, Dichgans, Martin, Saloner, David, Bos, Daniel, Jager, H. Rolf, Naylor, Ross, Faa, Gavino, Suri, Jasjit S., Costello, Justin, Auer, Dorothee P., Mcnally, J. Scott, Bonati, Leo H., Nardi, Valentina, van der Lugt, Aad, Griffin, Maura, Wasserman, Bruce A., Kooi, M. Eline, Gillard, Jonathan, Lanzino, Giuseppe, Mikhailidis, Dimitri P., Mandell, Daniel M., Benson, John C., van Dam-Nolen, Dianne H.K., Kopczak, Anna, Song, Jae W., Gupta, Ajay, DeMarco, J. Kevin, Chaturvedi, Seemant, Virmani, Renu, Hatsukami, Thomas S., Brown, Martin, Moody, Alan R., Libby, Peter, Schindler, Andreas, and Saam, Tobias

Published
2024
Full Text
View/download PDF

9. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Acosta, Julio, Al-Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Gouni-Berthold, Ioanna, Bhaskar, Sonu, Bielecka-Dąbrowa, Agata, Bjelakovic, Bojko, Bruckert, Eric, Bytyçi, Ibadete, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Chlebus, Krzysztof, Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, John Mancini, G.B., David Marais, A., Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Mohammad Nabavi, Seyed, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Serban, Maria-Corina, Shehab, Abdullah M.A, Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, von Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung-I, Zhisheng, Jiang, Zirlik, Andreas, Colletti, Alessandro, Mancini, John, Marais, David, Moriarty, Patrick, and Cicero, Arrigo Francesco Giuseppe

Published
2023
Full Text
View/download PDF

10. Why do guidelines recommend screening for abdominal aortic aneurysms, but not for asymptomatic carotid stenosis? A plea for a randomized controlled trial

Author

Paraskevas, Kosmas I., Spence, J. David, Mikhailidis, Dimitri P., Antignani, Pier Luigi, Gloviczki, Peter, Eckstein, Hans-Henning, Spinelli, Francesco, Stilo, Francesco, Saba, Luca, Poredos, Pavel, Dardik, Alan, Liapis, Christos D., Mansilha, Armando, Faggioli, Gianluca, Pini, Rodolfo, Jezovnik, Mateja K., Sultan, Sherif, Musiałek, Piotr, Goudot, Guillaume, Lavenson, George S., Jr, Jawien, Arkadiusz, Blinc, Aleš, Myrcha, Piotr, Fernandes e Fernandes, Jose, Geroulakos, George, Kakkos, Stavros K., Knoflach, Michael, Proczka, Robert M., Capoccia, Laura, Rundek, Tatjana, Svetlikov, Alexei S., Silvestrini, Mauro, Ricco, Jean-Baptiste, Davies, Alun H., Di Lazzaro, Vincenzo, Suri, Jasjit S., Lanza, Gaetano, Fraedrich, Gustav, Zeebregts, Clark J., and Nicolaides, Andrew N.

Published
2023
Full Text
View/download PDF

16. Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement

Author

Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Antignani, Pier Luigi, Baradaran, Hediyeh, Bokkers, Reinoud P.H., Cambria, Richard P., Dardik, Alan, Davies, Alun H., Eckstein, Hans-Henning, Faggioli, Gianluca, e Fernandes, Jose Fernandes, Fraedrich, Gustav, Geroulakos, George, Gloviczki, Peter, Golledge, Jonathan, Gupta, Ajay, Jezovnik, Mateja K., Kakkos, Stavros K., Katsiki, Niki, Knoflach, Michael, Kooi, M. Eline, Lanza, Gaetano, Liapis, Christos D., Loftus, Ian M., Mansilha, Armando, Millon, Antoine, Nicolaides, Andrew N., Pini, Rodolfo, Poredos, Pavel, Ricco, Jean-Baptiste, Riles, Thomas S., Ringleb, Peter Arthur, Rundek, Tatjana, Saba, Luca, Schlachetzki, Felix, Silvestrini, Mauro, Spinelli, Francesco, Stilo, Francesco, Sultan, Sherif, Suri, Jasjit S., Zeebregts, Clark J., and Chaturvedi, Seemant

Published
2022
Full Text
View/download PDF

17. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study

Author

Krzemień, Paweł, Kasperczyk, Sławomir, Banach, Maciej, Kasperczyk, Aleksandra, Dobrakowski, Michał, Tomasik, Tomasz, Windak, Adam, Mastej, Mirosław, Catapano, Alberico, Ray, Kausik K., Mikhailidis, Dimitri P., Toth, Peter P., Howard, George, Lip, Gregory Y. H., Tomaszewski, Maciej, Charchar, Fadi J., Sattar, Naveed, Williams, Bryan, MacDonald, Thomas M., Penson, Peter E., and Jóźwiak, Jacek J.

Published
2022
Full Text
View/download PDF

21. Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel

Author

Banach, Maciej, Gaita, Dan, Haluzik, Martin, Janez, Andrej, Kamenov, Zdravko, Kempler, Peter, Lalic, Nebojsa, Linhart, Ales, Mikhailidis, Dimitri P, Nocoń, Aleksandra, Silva Nunes, Jose, Papanas, Nikolaos, Raposo, Joao Filipe, Rizzo, Manfredi, and Pantea Stoian, Anca

Published
2021
Full Text
View/download PDF

36. Are We Using Ezetimibe As Much As We Should?

Author

Manolis, Antonis A, Manolis, Theodora A, Mikhailidis, Dimitri P, and Manolis, Antonis S

Subjects
EZETIMIBE, LDL cholesterol, STATINS (Cardiovascular agents), LOW density lipoproteins, CONTRAST media
Abstract

Lipid-lowering therapies, particularly non-statin regimens, are underutilized as ~2/3 of patients with atherosclerotic cardiovascular (CV) disease (CVD) are not optimally managed, and do not attain target low-density lipoprotein cholesterol (LDL-C) concentrations, despite statin treatment. Statins have been the mainstay of hypolipidemic therapies; however, they are plagued by adverse effects, which have partly hindered their more widespread use. Ezetimibe is often the first added mode of treatment to attain LDL-C goals as it is efficacious and also allows the use of a smaller dose of statin, while the need for more expensive therapies is obviated. We herein provide a comprehensive review of the effects of ezetimibe in lipid lowering and reducing CV events and improving outcomes. Of the hypolipidemic therapies, oral ezetimibe, in contrast to newer agents, is the most convenient and/or affordable regimen to be utilized as mono- or combined therapy supported by data from CV outcomes studies attesting to its efficacy in reducing CVD risk and events. When combined with a statin, the statin dose could be lower, thus curtailing side-effects, while the hypolipidemic effect is enhanced (by ~20%) as the percentage of patients with target level LDL-C (<70 mg/dL) is higher with combined treatment versus a high-intensity statin. Ezetimibe could also serve as an alternative treatment in cases of statin intolerance. In conclusion, ezetimibe has an excellent safety/tolerability profile; it is the first added treatment to a statin that can attain LDL-C targets. In the combined therapy, the hypolipidemic effect is enhanced while the dose of statin could be lower, thus limiting the occurrence of side-effects. Ezetimibe could also serve as an alternative mode of treatment in cases of statin intolerance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Celebrating the 90th birthday of the scientist who discovered statins: Akira Endō.

Author

Surma, Stanisław, Mikhailidis, Dimitri P, and Banach, Maciej

Subjects
DYSLIPIDEMIA, CARDIOVASCULAR diseases, STATINS (Cardiovascular agents), LDL cholesterol
Abstract

Dr. Akira Endō, the scientist who discovered statins, celebrated his 90th birthday in 2023. His discovery of statins revolutionized medicine and made them the gold standard for lipid-lowering treatment. Statins have been proven to improve cardiovascular outcomes and prolong life, reducing the risk of acute coronary syndrome, cardiovascular mortality, stroke, and other major cardiovascular events. However, statin intolerance is often overdiagnosed and misinformation about statins can lead to non-adherence. Combination therapy and improving adherence to statin treatment offer opportunities to further reduce LDL-C levels and improve cardiovascular outcomes. [Extracted from the article]

Published
2024
Full Text
View/download PDF

40. The Role of Nutraceuticals in Statin Intolerant Patients

Author

Banach, Maciej, Patti, Angelo Maria, Giglio, Rosaria Vincenza, Cicero, Arrigo F.G., Atanasov, Atanas G., Bajraktari, Gani, Bruckert, Eric, Descamps, Olivier, Djuric, Dragan M., Ezhov, Marat, Fras, Zlatko, von Haehling, Stephan, Katsiki, Niki, Langlois, Michel, Latkovskis, Gustavs, Mancini, G.B. John, Mikhailidis, Dimitri P., Mitchenko, Olena, Moriarty, Patrick M., Muntner, Paul, Nikolic, Dragana, Panagiotakos, Demosthenes B., Paragh, Gyorgy, Paulweber, Bernhard, Pella, Daniel, Pitsavos, Christos, Reiner, Željko, Rosano, Giuseppe M.C., Rosenson, Robert S., Rysz, Jacek, Sahebkar, Amirhossein, Serban, Maria-Corina, Vinereanu, Dragos, Vrablík, Michal, Watts, Gerald F., Wong, Nathan D., and Rizzo, Manfredi

Published
2018
Full Text
View/download PDF

47. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement

Author

Athyros, Vasilios G., Alexandrides, Theodore K., Bilianou, Helen, Cholongitas, Evangelos, Doumas, Michael, Ganotakis, Emmanuel S., Goudevenos, John, Elisaf, Moses S., Germanidis, Georgios, Giouleme, Olga, Karagiannis, Asterios, Karvounis, Charalambos, Katsiki, Niki, Kotsis, Vasilios, Kountouras, Jannis, Liberopoulos, Evangelos, Pitsavos, Christos, Polyzos, Stergios, Rallidis, Loukianos S., Richter, Dimitrios, Tsapas, Apostolos G., Tselepis, Alexandros D., Tsioufis, Konstantinos, Tziomalos, Konstantinos, Tzotzas, Themistoklis, Vasiliadis, Themistoklis G., Vlachopoulos, Charalambos, Mikhailidis, Dimitri P., and Mantzoros, Christos

Published
2017
Full Text
View/download PDF

49. Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview

Author

Telci Caklili,Ozge, Cesur,Mustafa, Mikhailidis,Dimitri P, and Rizzo,Manfredi

Subjects
Diabetes, Metabolic Syndrome and Obesity
Abstract

Ozge Telci Caklili,1 Mustafa Cesur,2 Dimitri P Mikhailidis,3 Manfredi Rizzo4 1Department of Endocrinology and Metabolism, Faculty of Medicine, University of Istanbul, Istanbul, Türkiye; 2Department of Endocrinology and Metabolism, Ankara Guven University Hospital, Ankara, Türkiye; 3Department of Clinical Biochemistry and Department of Surgical Biotechnology, Division of Surgery and Interventional Science, Medical School, University College London (UCL), London, UK; 4School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, ItalyCorrespondence: Manfredi Rizzo, School of Medicine, Promise Department, University of Palermo, Via del Vespro 141, Palermo, 90127, Italy, Tel/Fax +39 091 655-2945, Email manfredi.rizzo@unipa.itAbstract: Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.Keywords: obesity, drugs, liraglutide, semaglutide, tirzepatide, orlistat, phentermine/topiramate, bupropion/naltrexone

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results